FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 18:37:13 31/05/2024 BST | ||
| 1.28 EUR | +5.79% |
|
| Current month | +6.67% | ||
| 1 month | +6.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 1.28 | +5.79% |
| 30/05/24 | 1.21 | -6.92% |
| 29/05/24 | 1.3 | +4.84% |
| 28/05/24 | 1.24 | +12.73% |
| 27/05/24 | 1.1 | -3.51% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 06:37 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UH1ZFU |
| ISIN | DE000UH1ZFU8 |
| Date issued | 13/09/2021 |
| Strike | 80.1 $ |
| Maturity | Unlimited |
| Parity | 11.82 : 1 |
| Emission price | 5.11 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.08 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.03 € |
| Spread % | 2.38% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
